CIZ Cizzle Biotechnology Holdings Plc

TIDMCIZ

RNS Number : 2600E

Cizzle Biotechnology Holdings PLC

28 June 2023

28 June 2023

Cizzle Biotechnology Holdings Plc

("Cizzle Biotechnology" or the "Company")

Result of AGM

Cizzle Biotechnology, the UK-based diagnostics developer, announces that at the Annual General Meeting ("AGM") of the Company held earlier today, all resolutions were voted on by a show of hands and were passed.

The proxy votes cast in respect of the resolutions were as follows:

 
 Resolution                          For                 Against            Votes 
                                                                           withheld 
                             Total votes      %        Total       % 
                                                       votes 
                            -------------          ------------  -----  ------------ 
 1. To receive the 
  Company's annual 
  report and accounts 
  for the year ended 
  31 December 2022            89,757,080    97.11    2,672,935    2.89    1,661,693 
                            -------------  ------  ------------  -----  ------------ 
 2. To approve the 
  Directors' Remuneration 
  Report                       88,827,568   96.10    3,602,447    3.90    1,661,693 
                            -------------  ------  ------------  -----  ------------ 
 3. To re-appoint 
  Allan John Syms 
  as a Director of 
  the Company                  88,827,578   96.14     3,568,237   3.86    1,695,893 
                            -------------  ------  ------------  -----  ------------ 
 4. To re-appoint 
  PKF Littlejohn LLP 
  as auditor of the 
  Company                     88,861,778    96.14    3,568,237    3.86     1,661,693 
                            -------------  ------  ------------  -----  ------------ 
 5. To authorise 
  the Directors to 
  determine the auditor's 
  remuneration                88,861,778    96.14    3,568,237    3.86     1,661,693 
                            -------------  ------  ------------  -----  ------------ 
 6. Authorises the 
  Directors to allot 
  shares in the Company 
  or to grant rights 
  to subscribe for, 
  or to convert any 
  security into, shares 
  in the Company              88,661,778    95.92    3,768,237    4.08    1,661,693 
                            -------------  ------  ------------  -----  ------------ 
 7. Authorise the 
  Directors to allot 
  equity securities 
  disapplying pre-emption 
  rights                      88,823,568    96.10    3,606,437    3.90   1 ,661,703 
                            -------------  ------  ------------  -----  ------------ 
 8. That General 
  Meetings may be 
  called on not less 
  than 14 days' notice        88,861,778    96.14    3,568,237    3.86    1,661,693 
                            -------------  ------  ------------  -----  ------------ 
 

Enquiries:

 
 Cizzle Biotechnology Holdings     Via IFC Advisory 
  plc 
 Allan Syms (Executive Chairman) 
 
 
 Allenby Capital Limited    +44(0) 20 33285656 
 John Depasquale 
 Alex Brearley 
 
 
 Novum Securities Limited    +44(0) 20 7399 9400 
 Colin Rowbury 
  Jon Bellis 
 
 
 IFC Advisory Limited    +44(0) 20 3934 6630 
 Tim Metcalfe            cizzle@investor-focus.co.uk 
 Florence Chandler 
 

Notes to Editors:

About Cizzle Biotechnology

Cizzle Biotechnology is developing a blood test for the early detection of lung cancer. Cizzle Biotechnology is a spin- out from the University of York, founded in 2006 around the work of Professor Coverley and colleagues. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer.

For more information, please see https://cizzlebiotechnology.com

You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGSEUFSAEDSEIM

(END) Dow Jones Newswires

June 28, 2023 07:01 ET (11:01 GMT)

Cizzle Biotechnology (LSE:CIZ)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025

Cizzle Biotechnology (LSE:CIZ)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025